HAGGERTY POLICY SOLUTIONS for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Medicare/Medicaid MMM
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.